160 related articles for article (PubMed ID: 1681975)
1. Comparison of the effects of the novel vasodilator FK409 with those of nitroglycerin in isolated coronary artery of the dog.
Yamada H; Yoneyama F; Satoh K; Taira N
Br J Pharmacol; 1991 Jul; 103(3):1713-8. PubMed ID: 1681975
[TBL] [Abstract][Full Text] [Related]
2. Vasorelaxant mechanism of the new vasodilator, FK409.
Isono T; Koibuchi Y; Sato N; Furuichi A; Nishii M; Yamamoto T; Mori J; Kohsaka M; Ohtsuka M
Eur J Pharmacol; 1993 Aug; 246(3):205-12. PubMed ID: 7901040
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of the vasorelaxing action of (3E)-4-ethyl-2-hydroximino-5-nitro-3-hexamide FK409, a new vasodilator isolated from microbial sources, in isolated rabbit arteries.
Shibata S; Satake N; Sato N; Matsuo M; Koibuchi Y; Hester RK
J Cardiovasc Pharmacol; 1991 Mar; 17(3):508-18. PubMed ID: 1711615
[TBL] [Abstract][Full Text] [Related]
4. Nicorandil: differential contribution of K+ channel opening and guanylate cyclase stimulation to its vasorelaxant effects on various endothelin-1-contracted arterial preparations. Comparison to aprikalim (RP 52891) and nitroglycerin.
Borg C; Mondot S; Mestre M; Cavero I
J Pharmacol Exp Ther; 1991 Nov; 259(2):526-34. PubMed ID: 1682478
[TBL] [Abstract][Full Text] [Related]
5. Tolerance to the vascular effect of a novel nitric oxide-donating vasodilator, FK409.
Isono T; Sato N; Yamamoto T; Sawada T; Yamazaki S; Miura S; Furuichi A; Ozaki R; Koibuchi Y; Ohtsuka M
Eur J Pharmacol; 1994 Aug; 260(2-3):163-8. PubMed ID: 7988640
[TBL] [Abstract][Full Text] [Related]
6. Relationship between cyclic guanosine monophosphate accumulation and relaxation of canine trachealis induced by nitrovasodilators.
Zhou HL; Torphy TJ
J Pharmacol Exp Ther; 1991 Sep; 258(3):972-8. PubMed ID: 1679854
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor.
Merkel LA; Rivera LM; Perrone MH; Lappe RW
Eur J Pharmacol; 1992 May; 216(1):29-35. PubMed ID: 1326438
[TBL] [Abstract][Full Text] [Related]
8. Contribution of cyclic GMP formation to KRN2391-induced relaxation in coronary artery of the pig.
Jinno Y; Kasai H; Ohta H; Nishikori K; Fukushima H; Ogawa N
Br J Pharmacol; 1992 Aug; 106(4):906-9. PubMed ID: 1327392
[TBL] [Abstract][Full Text] [Related]
9. Dual mechanism of the relaxing effect of nicorandil by stimulation of cyclic GMP formation and by hyperpolarization.
Kukovetz WR; Holzmann S; Braida C; Pöch G
J Cardiovasc Pharmacol; 1991 Apr; 17(4):627-33. PubMed ID: 1711631
[TBL] [Abstract][Full Text] [Related]
10. Interactions of nitrovasodilators and atrial natriuretic peptide in isolated dog coronary arteries.
Matsumoto T; Okamura T; Kinoshita M; Toda N
Eur J Pharmacol; 1993 Jun; 237(1):31-7. PubMed ID: 8395391
[TBL] [Abstract][Full Text] [Related]
11. Comparison of nicorandil-induced relaxation, elevations of cyclic guanosine monophosphate and stimulation of guanylate cyclase with organic nitrate esters.
Greenberg SS; Cantor E; Ho E; Walega M
J Pharmacol Exp Ther; 1991 Sep; 258(3):1061-71. PubMed ID: 1679847
[TBL] [Abstract][Full Text] [Related]
12. cGMP-dependent protein kinase in regulation of basal tone and in nitroglycerin- and nitric-oxide-induced relaxation in porcine coronary artery.
Qin X; Zheng X; Qi H; Dou D; Raj JU; Gao Y
Pflugers Arch; 2007 Sep; 454(6):913-23. PubMed ID: 17377806
[TBL] [Abstract][Full Text] [Related]
13. Biphasic relaxant curves to glyceryl trinitrate in rat aortic rings. Evidence for two mechanisms of action.
Malta E
Naunyn Schmiedebergs Arch Pharmacol; 1989; 339(1-2):236-43. PubMed ID: 2566926
[TBL] [Abstract][Full Text] [Related]
14. Vasorelaxing effect of S-nitrosocaptopril on dog coronary arteries: no cross-tolerance with nitroglycerin.
Matsumoto T; Takahashi M; Nakae I; Kinoshita M
J Pharmacol Exp Ther; 1995 Dec; 275(3):1247-53. PubMed ID: 8531088
[TBL] [Abstract][Full Text] [Related]
15. Role of nitric oxide and guanosine 3',5'-cyclic monophosphate in mediating nonadrenergic, noncholinergic relaxation in guinea-pig pulmonary arteries.
Liu SF; Crawley DE; Rohde JA; Evans TW; Barnes PJ
Br J Pharmacol; 1992 Nov; 107(3):861-6. PubMed ID: 1335345
[TBL] [Abstract][Full Text] [Related]
16. Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast.
Pagani ED; VanAller GS; O'Connor B; Silver PJ
Eur J Pharmacol; 1993 Oct; 243(2):141-7. PubMed ID: 8276063
[TBL] [Abstract][Full Text] [Related]
17. Effect of FK409, a novel nitric oxide donor, on acute experimental myocardial ischemia.
Isono T; Sato N; Koibuchi Y; Sakai S; Yamamoto T; Ozaki R; Mori J; Kohsaka M; Ohtsuka M
Jpn J Pharmacol; 1993 Jul; 62(3):315-24. PubMed ID: 8411778
[TBL] [Abstract][Full Text] [Related]
18. Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo.
De Garavilla L; Pagani ED; Buchholz RA; Dundore R; Bode DC; Volberg ML; Jackson KN; Pratt P; Silver PJ
Eur J Pharmacol; 1996 Oct; 313(1-2):89-96. PubMed ID: 8905333
[TBL] [Abstract][Full Text] [Related]
19. Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular calcium and relaxation of rabbit aortic smooth muscle to nitric oxide.
Weisbrod RM; Griswold MC; Yaghoubi M; Komalavilas P; Lincoln TM; Cohen RA
Br J Pharmacol; 1998 Dec; 125(8):1695-707. PubMed ID: 9886761
[TBL] [Abstract][Full Text] [Related]
20. Potential greater than additive vasorelaxant actions of milrinone and nitroglycerin on human conduit arteries.
He GW; Yang CO; Gately H; Furnary A; Swanson J; Ahmad A; Floten S; Wood J; Starr A
Br J Clin Pharmacol; 1996 Feb; 41(2):101-7. PubMed ID: 8838435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
